Cubist Systematic Strategies’s Harvard Bioscience HBIO Stock Holding History

Cubist Systematic Strategies’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,414	Closed	-$40.3K	–	3192
2024 Q2	$40.3K	Buy	+1,414	New	+$49.6K	﹤0.01%	2727
2023 Q3	–	Sell	-3,312	Closed	-$182K	–	3574
2023 Q2	$182K	Buy	+3,312	New	+$182K	﹤0.01%	2851
2022 Q3	–	Sell	-2,294	Closed	-$83K	–	4541
2022 Q2	$83K	Buy	+2,294	New	+$104K	﹤0.01%	4013
2021 Q3	–	Sell	-1,328	Closed	-$111K	–	3043
2021 Q2	$111K	Buy	+1,328	New	+$93.9K	﹤0.01%	2707

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cubist Systematic Strategies's HBIO Position: Q3 2024 in Review

Cubist Systematic Strategies sold out of Harvard Bioscience (HBIO) in Q3 2024, closing a stake of 1,414 shares — an estimated $40.3K sold.

Cubist Systematic Strategies first reported a position in HBIO in Q2 2021 and held it in 4 quarters. The position peaked at $182K in Q2 2023. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2024.

Cubist Systematic Strategies reported no remaining Harvard Bioscience position as of Q3 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 1,414 Harvard Bioscience shares in Q3 2024, an estimated $40.3K.
Cubist Systematic Strategies first reported a position in Harvard Bioscience in Q2 2021 and held it in 4 quarters.
Cubist Systematic Strategies's Harvard Bioscience position peaked at $182K in Q2 2023.
94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2024.

Based on Cubist Systematic Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.